Opus Genetics, Inc. IRD
4.31 USD +0.08 (+1.89%)
At closeNov 11, 2026, 4:01 PM EST
4.31 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
4.13 Day range 4.52
1.70 52-week range 7.07
- YTD
- +114.43%
- 1 year
- +118.78%
News
benzinga.com RBC Capital Maintains Outperform on Opus Genetics, Raises Price Target to $11 RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $9 to $11.
benzinga.com HC Wainwright & Co. Maintains Buy on Opus Genetics, Raises Price Target to $14 HC Wainwright & Co. analyst Matthew Caufield maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $8 to $14.
zacks.com Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.12 per share a year ago.
benzinga.com Opus Genetics Q3 EPS $(0.46) Misses $(0.15) Estimate, Sales $1.137M Miss $1.959M Estimate Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.15) by 206.67 percent. This is a 84 percent decrease over losses of…
globenewswire.com Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Clearance of IND for…
globenewswire.com Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene…- benzinga.com FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early…
benzinga.com Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with
benzinga.com Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $17 price target.
benzinga.com Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.- benzinga.com Opus Genetics Presents Clinical Findings From OPGx-BEST1 And OPGx-LCA5 Gene Therapy Programs At Retina In Rio 2026; Phase 3 Clinical Trial Dosing For OPGx-LCA5 Expected In Q4 Of 2026 OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical developmentNew…
benzinga.com Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13 Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.- benzinga.com Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20 Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
benzinga.com Crude Oil Jumps Over 3%; Core & Main Posts Upbeat Q2 Earnings U.S. stocks fell Wednesday as energy rose and discretionary slumped; Signet and Opus surged, while ServiceTitan plunged. Oil jumped 3.6%.
benzinga.com Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.
benzinga.com Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
benzinga.com Dow Tumbles 350 Points; Signet Jewelers Shares Jump Following Upbeat Q2 Earnings U.S. stocks fell Wednesday, led by a 350-point Dow drop. Signet surged on strong earnings; oil, gold and silver prices climbed.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding…
benzinga.com Opus Genetics Announces Results From Low-Dose Cohort 1 Of BIRD-1, Ongoing Phase 1/2 Clinical Trial Evaluating Opgx-BEST1 Showing Favorable Safety, Tolerability Profile With No Serious Adverse Events Or Dose-Limiting Toxicities Observed OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful…- benzinga.com Opus Genetics Plans To Present Topline Clinical Data From Cohort 1 Of Its Phase 1/2 Study Of OPGx-BEST1 During Investor Conference Call And Webcast On September 9 Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ETFull clinical dataset and additional…
benzinga.com RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9 RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.- benzinga.com Opus Genetics Files Prospectus To Sell $300M Mixed Securities Shelf Including 34.5M Shares Common StockPreferred StockDebt SecuritiesWarrantsUnitsand up to 34,449,749 Shares of Common Stock Issuable Upon Exercise ofWarrants and Pre-Funded Warrants Offered, from time to time, by…
- benzinga.com Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12)…
- benzinga.com Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease Topline six-month efficacy data expected by end of 2027Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) programOpus Genetics may…
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In July Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.
benzinga.com Opus Genetics Expects To Announce Three-month Topline Data From Cohort 1 Of Phase 1/2 Trial Of OPGx-BEST1 For Best Vitelliform Macular Dystrophy Or Autosomal-recessive Bestrophinopath, During The Second Week Of September 2026 Opus Genetics, Inc. (NASDAQ:IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in
benzinga.com Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 For Early-Onset Severe Inherited Retinal Dystrophy Opus Genetics has received the meeting minutes from the Type B meeting confirming several key elements of the trial. The Phase 3 study is expected to enroll eight participants who are able to…- benzinga.com Opus Genetics Set To Join Russell 3000, 2000, Microcap Indexes, Effective June 29 Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with
- benzinga.com Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13 Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $11 to $13.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
- benzinga.com Citizens Reiterates Market Outperform on Opus Genetics, Maintains $11 Price Target Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $11 price target.
- benzinga.com Opus Genetics Files Prospectus For Offering 2.679M Common Shares On Behalf Of Selling Shareholders https://www.sec.gov/Archives/edgar/data/1228627/000114036126024283/ny20075388x1_s3.htm
- benzinga.com Guggenheim Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $16 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Price Target of $16.
- benzinga.com Leerink Partners Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $10 Leerink Partners analyst Lili Nsongo initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outperform rating and announces Price Target of $10.
- benzinga.com Citizens Maintains Market Outperform on Opus Genetics, Lowers Price Target to $11 Citizens analyst Jonathan Wolleben maintains Opus Genetics (NASDAQ:IRD) with a Market Outperform and lowers the price target from $12 to $11.
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com Opus Genetics Q1 EPS $(0.75) Misses $(0.14) Estimate, Sales $2.157M Miss $2.931M Estimate Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.14) by 435.71 percent. This is a 212.5 percent decrease over losses of…
- benzinga.com Opus Genetics Announces New Clinical And Preclinical Data From Multiple Programs Presented At Association For Research In Vision And Opthalmology Annual Meeting May 3-7 Oral PresentationRestoration of Cone-Mediated Vision After Gene Augmentation in Children with LCA5The oral presentation, delivered by Tomas S. Aleman, M.D., primary study investigator, reported…
benzinga.com This Live Nation Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. See all changes, including upgrades and downgrades, on analyst ratings page.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.
benzinga.com Viatris Eye Drops Data Shows Promise For Blurred Near Vision Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.- benzinga.com Viatris And Opus Genetics Say VEGA-3 Phase 3 Trial Meets Primary And Key Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related…
- benzinga.com Viatris And Opus Genetics Report Top-Line Results From VEGA-3, Second Pivotal Phase 3 Trial Evaluating MR-141 In Treating Presbyopia; Targets Application To FDA In H2 2025 MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance VisionSafety Profile Consistent With Previous…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session